ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN

But 'Unique Side Effects' A Concern

 
• By Kevin Grogan
  
Lung Cancer
Pfizer pushing in ALK-Positive lung cancer space • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D